Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $100824.0.

  • Seres Therapeutics' Treasury Shares fell 9634.03% to $100824.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100824.0, marking a year-over-year decrease of 9634.03%. This contributed to the annual value of $81459.0 for FY2024, which is 9758.84% down from last year.
  • Seres Therapeutics' Treasury Shares amounted to $100824.0 in Q3 2025, which was down 9634.03% from $51199.0 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Treasury Shares registered a high of $4.2 million during Q1 2023, and its lowest value of $51199.0 during Q2 2025.
  • Moreover, its 5-year median value for Treasury Shares was $1.6 million (2022), whereas its average is $1.8 million.
  • As far as peak fluctuations go, Seres Therapeutics' Treasury Shares soared by 1120392.31% in 2021, and later plummeted by 9865.53% in 2025.
  • Seres Therapeutics' Treasury Shares (Quarter) stood at $734755.0 in 2021, then surged by 110.89% to $1.5 million in 2022, then surged by 117.99% to $3.4 million in 2023, then plummeted by 97.59% to $81459.0 in 2024, then grew by 23.77% to $100824.0 in 2025.
  • Its Treasury Shares stands at $100824.0 for Q3 2025, versus $51199.0 for Q2 2025 and $76477.0 for Q1 2025.